Spironolactone may be used alone or with thiazides. It is indicated in patients with CHF taking digitalis when other therapies are considered inappropriate. Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy, in combination with bed rest and the restriction of fluid and sodium. However, spironolactone has not been shown to affect the basic pathological process.
Spironolactone alone has mild to moderate antihypertensive activity.
Spironolactone is indicated for treatment of hypokalemia when other measures are considered inappropriate or inadequate. It is also indicated for the prophylaxis of hypokalemia in digitalis therapy when other measures are inadequate or inappropriate. Excessive potassium intake may cause hyperkalemia in patients receiving spironolactone. Do not administer spironolactone concurrently with other potassium sparing diuretics. Spironolactone, in chronic toxicity studies, has been shown to be a tumorigen in rats.